The Southampton, Hampshire, Isle of Wight and Portsmouth Primary Care Trust Cluster (SHIP) has said that it has now stopped using cancer drug Avastin after a legal challenge from Novartis.
The British health authority had turned to the alternative as a cheaper solution to Lucentis, despite it not being licensed for treating eye conditions.
Novartis sought a judicial review earlier this year and said that the use of Avastin could risk the safety of patients, reported Reuters.
The decision to drop the alternative has been welcomed by the Association of the British Pharmaceutical Industry, which supported Novartis in the case.
"The board agreed that taking advantage of the significant discounts now being made available by Novartis, which have been introduced since the policy was agreed, was in the best interests of local patients," said professor Jonathan Montgomery, chair of the PCT Cluster Board.
He added that the board also took into account the fact that the policy had not been taken up by consultant ophthalmologists on the advice of their Royal College, which meant that the potential benefits of offering Avastin and Lucentis had not been realised.